TKG Advisors LLC acquired a new stake in Jones Lang LaSalle Incorporated (NYSE:JLL – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 18,577 shares of the financial services provider’s stock, valued at approximately $5,012,000. Jones Lang LaSalle comprises 2.5% of TKG Advisors LLC’s investment portfolio, making the stock its 10th largest holding.
A number of other large investors have also recently bought and sold shares of JLL. Massmutual Trust Co. FSB ADV boosted its stake in shares of Jones Lang LaSalle by 37.5% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 143 shares of the financial services provider’s stock worth $39,000 after acquiring an additional 39 shares in the last quarter. Parallel Advisors LLC raised its position in shares of Jones Lang LaSalle by 3.1% in the second quarter. Parallel Advisors LLC now owns 1,625 shares of the financial services provider’s stock valued at $334,000 after purchasing an additional 49 shares during the period. First Bank & Trust boosted its holdings in shares of Jones Lang LaSalle by 2.5% during the 3rd quarter. First Bank & Trust now owns 2,251 shares of the financial services provider’s stock worth $607,000 after buying an additional 54 shares during the period. Van ECK Associates Corp grew its stake in Jones Lang LaSalle by 0.5% in the 3rd quarter. Van ECK Associates Corp now owns 11,390 shares of the financial services provider’s stock valued at $2,972,000 after buying an additional 54 shares during the last quarter. Finally, Tandem Capital Management Corp ADV lifted its position in Jones Lang LaSalle by 0.4% during the 2nd quarter. Tandem Capital Management Corp ADV now owns 13,747 shares of the financial services provider’s stock worth $2,779,000 after acquiring an additional 55 shares during the last quarter. 94.80% of the stock is currently owned by institutional investors.
Jones Lang LaSalle Price Performance
Shares of Jones Lang LaSalle stock traded up $2.31 during trading on Monday, hitting $267.31. 12,351 shares of the company’s stock traded hands, compared to its average volume of 281,572. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.58 and a quick ratio of 2.58. The firm’s fifty day moving average price is $261.44 and its 200 day moving average price is $229.03. The company has a market cap of $12.69 billion, a PE ratio of 33.46 and a beta of 1.37. Jones Lang LaSalle Incorporated has a twelve month low of $136.83 and a twelve month high of $280.48.
Wall Street Analysts Forecast Growth
JLL has been the subject of several research analyst reports. Raymond James boosted their price objective on Jones Lang LaSalle from $246.00 to $268.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 25th. Keefe, Bruyette & Woods upped their target price on shares of Jones Lang LaSalle from $240.00 to $250.00 and gave the company a “market perform” rating in a research note on Thursday, August 8th. Finally, StockNews.com raised shares of Jones Lang LaSalle from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 13th. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $246.80.
Read Our Latest Stock Report on JLL
About Jones Lang LaSalle
Jones Lang LaSalle Incorporated operates as a commercial real estate and investment management company. It engages in the buying, building, occupying, managing, and investing in a commercial, industrial, hotel, residential, and retail properties in Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Featured Articles
- Five stocks we like better than Jones Lang LaSalle
- Election Stocks: How Elections Affect the Stock Market
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Why Invest in High-Yield Dividend Stocks?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
- Differences Between Momentum Investing and Long Term Investing
- 3 Stocks That Are Potential Takeover Targets in 2025
Receive News & Ratings for Jones Lang LaSalle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jones Lang LaSalle and related companies with MarketBeat.com's FREE daily email newsletter.